Prometheus Biosciences, Inc., A Subsidiary Of Merck & Co., Inc. (rahway, New Jersey Usa)

This study is testing whether an investigational drug called tulisokibart can safely slow the progression of lung scarring in people with systemic sclerosis, a rare autoimmune disease. The trial involves 154 participants who will receive either the drug or a placebo for 50 weeks …